FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs
